CD4 and sarcopenia: Multivariate analysis further elucidated independent prognostic factors for PFS, highlighting that pTNM stage (HR = 4.956, 95% CI: 2.797–8.781, P < 0.001), CD19+ cells (HR = 0.230, 95% CI: 0.055–0.961, P = 0.044), sarcopenia (HR = 4.343, 95% CI: 1.285–14.678, P = 0.018) and CD3+/CD4+ cell–myosteatosis (P < 0.001) were significant contributors (Table 2).